MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

Search

Ligand Pharmaceuticals Inc

Deschisă

SectorSănătate

194.52 2.06

Rezumat

Modificarea prețului

24h

Curent

Minim

189.1

Maxim

195.2

Indicatori cheie

By Trading Economics

Venit

112M

117M

Vânzări

115M

P/E

Medie Sector

86.354

88.032

Marjă de profit

101.569

Angajați

68

EBITDA

87M

149M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+28.08% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-278M

3.8B

Deschiderea anterioară

192.46

Închiderea anterioară

194.52

Sentimentul știrilor

By Acuity

21%

79%

39 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 ian. 2026, 18:06 UTC

Principalele dinamici ale pieței

LifeMD Shares Rise After Company Offers Novo Nordisk's Wegovy

5 ian. 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 ian. 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

5 ian. 2026, 23:51 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

5 ian. 2026, 23:42 UTC

Market Talk
Evenimente importante

Gold Edges Lower on Likely Technical Correction -- Market Talk

5 ian. 2026, 21:52 UTC

Evenimente importante

Oil Stocks, Banks Push Dow to New Record -- WSJ

5 ian. 2026, 21:51 UTC

Evenimente importante

Palantir Stock Jumps. How It Benefited from the Venezuela Raid. -- Barrons.com

5 ian. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 ian. 2026, 21:38 UTC

Evenimente importante

Stock Market Today: Dow Jumps to Record After U.S. Captures Venezuela's Maduro -- WSJ

5 ian. 2026, 21:09 UTC

Achiziții, Fuziuni, Preluări

SGH, Steel Dynamics Won't Need to Raise Equity to Fund Transaction

5 ian. 2026, 21:09 UTC

Achiziții, Fuziuni, Preluări

SGH, Steel Dynamics to Fund Transaction With Cash, Available Debt Financing

5 ian. 2026, 21:08 UTC

Achiziții, Fuziuni, Preluări

SGH Proposes Minimum One Board Position for BlueScope Directors to Maintain Continuity

5 ian. 2026, 21:06 UTC

Achiziții, Fuziuni, Preluări

SGH, Steel Dynamics Offer Values BlueScope's Equity at A$13.2 Billion

5 ian. 2026, 21:06 UTC

Achiziții, Fuziuni, Preluări

SGH Would Retain Remainder of BlueScope's Operations if Deal Completes

5 ian. 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

SGH Would Sell BlueScope's North American Operations to Steel Dynamics if Deal Completes

5 ian. 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

SGH, Steel Dynamics Offering A$30.00/Share in Cash to Acquire BlueScope

5 ian. 2026, 21:04 UTC

Achiziții, Fuziuni, Preluări

SGH, Steel Dynamics Make Takeover Offer for BlueScope Steel

5 ian. 2026, 20:18 UTC

Market Talk

U.S. Natural Gas Extends Losses on Milder Weather Outlook -- Market Talk

5 ian. 2026, 20:08 UTC

Market Talk

Venezuela Needs Billions in Investment for Oil-Production Growth -- Market Talk

5 ian. 2026, 19:16 UTC

Market Talk
Evenimente importante

Alberta Says Canada Needs to Expedite Pipeline Projects Following Trump's Venezuela Move -- Market Talk

5 ian. 2026, 18:57 UTC

Market Talk
Evenimente importante

Quick Return of Venezuelan Oil Barrels A Possibility -- Market Talk

5 ian. 2026, 18:23 UTC

Market Talk

Moody's Should See Boost from Strong Debt Issuance Year -- Market Talk

5 ian. 2026, 18:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 ian. 2026, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

5 ian. 2026, 18:08 UTC

Market Talk
Evenimente importante

Canadian Heavy Oil Producers at Risk From a Revitalized Venezuela -- Market Talk

5 ian. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 ian. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 ian. 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 ian. 2026, 17:08 UTC

Câștiguri

Strategy Records $17.44 Billion Unrealized Loss in Fourth Quarter -- WSJ

Comparație

Modificare preț

Ligand Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

28.08% sus

Prognoză pe 12 luni

Medie 243.5 USD  28.08%

Maxim 275 USD

Minim 220 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLigand Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

7

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

102.5 / 109.24Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

39 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat